FollowMyHealth Patient Portal

Alan Pestronk, MD

Professor, Neurology
Section Chief, Neuromuscular Diseases
Professor, Pathology
Director, Neuromuscular Clinical Laboratory

Specialty Areas

Nerve Disorders
Neuromuscular Disease
Neurology - Adult
Muscle Disorders
Muscular Dystrophy
ALS - Lou Gehrig's Disease
Myasthenia Gravis

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital
St. Louis Children's Hospital

Areas of Clinical Interest

Clinical neurology, neuromuscular disease, neuroimmunology, glycolipids, proteoglycans, aging and the nervous system, history of neurology, myopathy, neuropathy, weakness, myasthenia, muscle, nerve, numbness, sensory loss, pain, fatigue, muscular dystrophy, neuro muscular.



More Information on the Neuromuscular Disease Center

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Neuroscience Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: 314-362-6981
Fax: 314-362-3752

Education

Education

Chief Residency: Neurology, Johns Hopkins Hospital, Baltimore, Maryland 1974
Fellowship: Neuromuscular Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 1977
Residency: Neurology, Johns Hopkins Hospital, Baltimore, Maryland 1973
Medical Degree: Johns Hopkins School of Medicine, Baltimore, Maryland 1970
B.A.: Princeton University, Princeton, New Jersey 1966

Publication & Research

Publication & Research

Clinical and Laboratory Profiles of Idiopathic Small Fiber Neuropathy in Children: Case Series.
Kafaie J, Al Balushi A, Kim M, Pestronk A
J Clin Neuromuscul Dis. 2017 Sep; 19(1)31-37. doi: 10.1097/CND.0000000000000178.

PMID:
    28827487
    [PubMed - in process]
Related citations


Characterization of Strength and Function in Ambulatory Adults With GNE Myopathy.
Argov Z, Bronstein F, Esposito A, Feinsod-Meiri Y, Florence JM, Fowler E, Greenberg MB, Malkus EC, Rebibo O, Siener CS, Caraco Y, Kolodny EH, Lau HA, Pestronk A, Shieh P, Skrinar AM, Mayhew JE
J Clin Neuromuscul Dis. 2017 Sep; 19(1)19-26. doi: 10.1097/CND.0000000000000181.

PMID:
    28827485
    [PubMed - in process]
Related citations


Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.
Anderson J, Seol H, Gordish-Dressman H, Hathout Y, Spurney CF, CINRG Investigators.
Pediatr Cardiol. 2017 Aug 18; doi: 10.1007/s00246-017-1703-9.

PMID:
    28821969
    [PubMed - as supplied by publisher]
Related citations


Survival among children with "Lethal" congenital contracture syndrome 11 caused by novel mutations in the gliomedin gene (GLDN).
Wambach JA, Stettner GM, Haack TB, Writzl K, Škofljanec A, Maver A, Munell F, Ossowski S, Bosio M, Wegner DJ, Shinawi M, Baldridge D, Alhaddad B, Strom TM, Grange DK, Wilichowski E, Troxell R, Collins J, Warner BB, Schmidt RE, Pestronk A, Cole FS, Steinfeld R
Hum Mutat. 2017 Nov; 38(11)1477-1484. doi: 10.1002/humu.23297.

PMID:
    28726266
    [PubMed - in process]
Related citations


Cystinosis distal myopathy, novel clinical, pathological and genetic features.
Cabrera-Serrano M, Junckerstorff RC, Alisheri A, Pestronk A, Laing NG, Weihl CC, Lamont PJ
Neuromuscul Disord. 2017 Sep; 27(9)873-878. doi: 10.1016/j.nmd.2017.05.010.

PMID:
    28629674
    [PubMed - in process]
Related citations


Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy.
Hogarth MW, Houweling PJ, Thomas KC, Gordish-Dressman H, Bello L, Cooperative International Neuromuscular Research Group (CINRG)., Pegoraro E, Hoffman EP, Head SI, North KN
Nat Commun. 2017 Jan 31; 814143. doi: 10.1038/ncomms14143.

PMID:
    28139640
    [PubMed - in process]
Related citations


Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study.
Argov Z, Caraco Y, Lau H, Pestronk A, Shieh PB, Skrinar A, Koutsoukos T, Ahmed R, Martinisi J, Kakkis E
J Neuromuscul Dis. 2016 Mar 3; 3(1)49-66.

PMID:
    27854209
    [PubMed - in process]
Related citations


Sarcopenia, age, atrophy, and myopathy: Mitochondrial oxidative enzyme activities.
Pestronk A, Keeling R, Choksi R
Muscle Nerve. 2017 Jul; 56(1)122-128. doi: 10.1002/mus.25442.

PMID:
    27759889
    [PubMed - indexed for MEDLINE]
Related citations


Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.
Bello L, Flanigan KM, Weiss RB, United Dystrophinopathy Project., Spitali P, Aartsma-Rus A, Muntoni F, Zaharieva I, Ferlini A, Mercuri E, Tuffery-Giraud S, Claustres M, Straub V, Lochmüller H, Barp A, Vianello S, Pegoraro E, Punetha J, Gordish-Dressman H, Giri M, McDonald CM, Hoffman EP, Cooperative International Neuromuscular Research Group.
Am J Hum Genet. 2016 Nov 3; 99(5)1163-1171. doi: 10.1016/j.ajhg.2016.08.023.

PMID:
    27745838
    [PubMed - indexed for MEDLINE]
Related citations


The Clinical Outcome Study for dysferlinopathy: An international multicenter study.
Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, Smith FE, Rufibach L, Cnaan A, Bharucha-Goebel DX, Blamire AM, Bravver E, Carlier PG, Day JW, Díaz-Manera J, Eagle M, Grieben U, Harms M, Jones KJ, Lochmüller H, Mendell JR, Mori-Yoshimura M, Paradas C, Pegoraro E, Pestronk A, Salort-Campana E, Schreiber-Katz O, Semplicini C, Spuler S, Stojkovic T, Straub V, Takeda S, Rocha CT, Walter MC, Bushby K, Jain COS Consortium.
Neurol Genet. 2016 Aug; 2(4)e89. doi: 10.1212/NXG.0000000000000089.

PMID:
    27602406
    [PubMed]
Related citations


Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM
Neurology. 2016 Nov 15; 87(20)2123-2131.

PMID:
    27566742
    [PubMed - indexed for MEDLINE]
Related citations


Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Bjartmar C, Thurberg BL
Mol Genet Metab. 2016 Sep; 119(1-2)115-23. doi: 10.1016/j.ymgme.2016.05.013.

PMID:
    27473031
    [PubMed - in process]
Related citations


Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM
J Neurol Neurosurg Psychiatry. 2017 Feb; 88(2)99-105. doi: 10.1136/jnnp-2016-313521.

PMID:
    27261500
    [PubMed - indexed for MEDLINE]
Related citations


A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME, Mexiletine ALS Study Group.
Neurology. 2016 Apr 19; 86(16)1474-81. doi: 10.1212/WNL.0000000000002507.

PMID:
    26911633
    [PubMed - indexed for MEDLINE]
Related citations


Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.
Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A, Meola G, Conwit R, Hanna MG, Griggs RC, Muscle Study Group.
Neurology. 2016 Apr 12; 86(15)1408-16. doi: 10.1212/WNL.0000000000002416.

PMID:
    26865514
    [PubMed - indexed for MEDLINE]
Related citations


Bicaudate infarcts in the setting of congenital absence of A<sub>1</sub> segment.
Tahsili-Fahadan P, Yahyavi-Firouz-Abadi N, Keyrouz SG, Pestronk A
Neurol Clin Pract. 2015 Dec; 5(6)540-541.

PMID:
    26716067
    [PubMed]
Related citations


MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs.
Albulym OM, Kennerson ML, Harms MB, Drew AP, Siddell AH, Auer-Grumbach M, Pestronk A, Connolly A, Baloh RH, Zuchner S, Reddel SW, Nicholson GA
Ann Neurol. 2016 Mar; 79(3)419-27. doi: 10.1002/ana.24575.

PMID:
    26659848
    [PubMed - indexed for MEDLINE]
Related citations


SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles.
Bucelli RC, Arhzaouy K, Pestronk A, Pittman SK, Rojas L, Sue CM, Evilä A, Hackman P, Udd B, Harms MB, Weihl CC
Neurology. 2015 Aug 25; 85(8)665-74. doi: 10.1212/WNL.0000000000001864.

PMID:
    26208961
    [PubMed - indexed for MEDLINE]
Related citations


Nerve ultrasound identifies abnormalities in the posterior interosseous nerve in patients with proximal radial neuropathies.
Dietz AR, Bucelli RC, Pestronk A, Zaidman CM
Muscle Nerve. 2016 Mar; 53(3)379-83. doi: 10.1002/mus.24778.

PMID:
    26201950
    [PubMed - indexed for MEDLINE]
Related citations


Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology.
Alshehri A, Choksi R, Bucelli R, Pestronk A
Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4)e124. doi: 10.1212/NXI.0000000000000124.

PMID:
    26090508
    [PubMed]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2016.

Company Name: Athena Diagnostics

Royalties: $25,001 - $50,000

Equity: No

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2017